Precision NanoSystems (PNI), a biotechnology company pioneering innovative solutions for the development of genetic nanomedicines for gene and cell therapy used in oncology, rare disease and infectiousdisease, today announced that Dr. James Taylor, PNI’s Chief Executive Officer and Co-founder, will make a company presentation titled, "How NxGen Technology Will Drive the Creation of Transformative Nanomedicines." About Precision NanoSystems Inc. Precision NanoSystems Inc. (PNI) proprietary NanoAssemblr Platform enables the rapid, reproducible, and scalable manufacture of next generation nanoparticle formulations for the targeted delivery of therapeutic and diagnostic agents to cells and tissues in the body. PNI provides instruments, reagents and services to life sciences researchers, including pharmaceutical companies, and builds strategic collaborations to revolutionize healthcare through nanotechnology. For more information, visit www.precisionnanosystems.com.
Company HQ State:
Company HQ Country:
Main Therapeutic Focus:
Lead Product in Development:
None. PNI is a platform company delivering solutions to other pharma to develop therapeutics
Development Phase of Primary Product:
Number Of Unlicensed Products (For Which You Are Seeking Partners):